Blavatnik Biomedical Accelerator

 

Blavatnik Fellowship in Life Science Entrepreneurship 

 

Entrepreneurs play a crucial role in successful commercialization of new biomedical technologies. The Blavatnik Fellowship in Life Science Entrepreneurship is designed to foster entrepreneurial skills in the life sciences, linking emerging business leaders with breakthrough innovations from across Harvard University. 

This innovative fellowship program provides a select group of Harvard Business School MBA alumni with the opportunity to work with Harvard inventors to promote the commercialization of life science technologies with significant market potential. Harvard's i-lab serves as the hub, providing fellows with space and the opportunity to join an entrepreneurial community. 

Blavatnik Fellows enjoy a unique set of advantages:

  • Mentorship by distinguished business and science leaders of Boston's biopharma and health technology communities    
  • Leadership opportunities, including the opportunity to join and develop founding teams of new ventures    
  • Education and training on a range of topics, including commercial strategy, R&D management, intellectual property, regulatory affairs, business development, and entrepreneurial financing    
  • Financial support in the form of a one-year stipend plus access to funding for due diligence, market research, licensing options and other commercial activities arising from the fellowship 

The Blavatnik Fellowship in Life Science Entrepreneurship is led by Vicki Sato, Ph.D., Professor of Management Practice at Harvard Business School.

Program Details and Application Process 

Admission to the fellowship is competitive and open to HBS MBA alumni who have graduated within the last 7 years. More information can be found in the Program Description below.

Complete Program Description

For further information contact:  blavatnikfellowship@hbs.edu


Blavatnik Fellows 

The fourth group of Blavatnik Fellows is in place for 2016-2017.  Meet the Group

Past Blavatnik Fellows:
Blavatnik Fellows 2015-16
Blavatnik Fellows 2014-15
Blavatnik Fellows 2013-14


View this video of achievements and lessons from the inaugural Blavatnik Fellowship in Life Science Entrepreneurship


By bringing together expertise and experience from across Harvard, the Accelerator and the HBS Fellows program will further enhance Harvard’s commitment to innovative research and entrepreneurship.

Dean Nitin Nohria

Harvard Business School
 

2016–17 Fellows

Raffaella_SquilloniRaffaella Squilloni (MBA 2010) comes to the Blavatnik Fellowship with a deep passion for emerging zoonotic infectious diseases and viral hemorrhagic fevers. She has spent this past year developing and validating point-of-care molecular diagnostics for Zika, Ebola, and HIV. Prior to making her foray into biotech, she had extensive experience working with emerging and frontier markets and on the buy-side in finance. After graduating from HBS, she worked for a New York-based private equity fund specializing in emerging and frontier markets and co-founded a specialty mineral startup developing calcium carbonate mines in the Caribbean Basin and East Africa. Squilloni spent several years at Goldman Sachs working for their European Special Situations Group hedge fund and on the trading floor on synthetic CDOs and structured credit derivatives. She also holds a BSc from the London School of Economics and an MSc from the London School of Economics and the University of Chicago.

Manny SimonsManny Simons (MBA 2012) is a scientist and entrepreneur with experience building new ventures focused on the discovery and development of novel therapeutics. Prior to becoming a Blavatnik Fellow, he was director of business development at Voyager Therapeutics, a gene therapy company concentrating on severe central nervous system disorders. As a core member of the business team at Voyager, he worked to establish and manage Voyager's $845 million strategic collaboration with Sanofi Genzyme as well as help the company raise over $170 million in equity capital, including the successful completion of an initial public offering in 2015. Prior to his role at Voyager, Simons led licensing and was head of corporate development at Warp Drive Bio, which launched with a $125 million investment by Third Rock Ventures and Sanofi in 2012. Earlier in his career, Simons was an Entrepreneurial Fellow at Flagship Ventures, where he was a member of the founding team of Seres Therapeutics. He earned an AB magna cum laude in neuroscience and music from Harvard College and a PhD in biomedical engineering from MIT, where he studied with Institute Professor Robert Langer.

Jon PuzJon Puz (MBA 2008) is an entrepreneurial executive with a background in launching, scaling, and advising healthcare technology companies. Since completing his MBA, he has served as a key leader and driven the growth of three successful ventures that have focused on digital health, predictive analytics, and improving patient outcomes. His senior-level leadership roles have included strategy, business development, finance, product development, operations, and technology. While pursuing his MBA, Puz collaborated with the Whitesides Research Group and co-wrote the business plan for Diagnostics For All (DFA), which is the only organization to ever win both the HBS New Venture Competition and the MIT $100K. He also helped launch DFA and served as advisor. Prior to HBS, Puz served as a strategy and operations consultant in the healthcare practice at Deloitte Consulting. Along with his Harvard MBA, he also holds a BS in computer science and systems analysis from Miami University (Ohio).

Kouki_HarasakiKouki Harasaki (MBA 2011) began his career in clinical research and lab research positions at the Cleveland Clinic Foundation and the National Institutes of Health, respectively. Since winning a UK national biotech competition in 2003, he has been focused on developing new technologies that impact patients. After earning his PhD, he spent six years in drug discovery, animal pharmacology, strategy, finance, and business development positions at Novartis AG. He has also held positions at Sofinnova Ventures, Genentech, GlaxoSmithKline, Dr. Reddy’s Laboratories, and iPierian. Most recently, Harasaki was a Senior Director of Business Development at Baxalta (now Shire). There he was instrumental in building the immuno-oncology pipeline by negotiating $5 billion in licensing transactions in two years, including the co-development of the marketed pancreatic cancer drug ONIVYDE®. Harasaki earned a BA in molecular/cell biology and Asian studies from Cornell University (cum laude) and a PhD in clinical biochemistry from the University of Cambridge (Wellcome Trust Fellow). At HBS he was a Robert S. Kaplan Fellow. He is currently a board member of the Harvard Business School Healthcare Alumni Association.

Alan_BralyAlan Braly (MBA 2010) joins the Blavatnik Fellowship from Health Advances, a boutique healthcare consulting firm, where he was a member of the management team within the medtech practice. At Health Advances, he led engagements across almost every major therapeutic area and device category, helping clients solve a wide range of product and technology commercial strategy challenges. His clients included both startups and existing public medical device companies. He also worked extensively with both financial and strategic buyers on the due diligence of medtech acquisitions. Prior to graduate school, Braly worked in R&D as a biomedical engineer in Medtronic’s cardiac rhythm management business unit. There his experience included new materials development, preclinical and clinical research, and new technology portfolio strategy. He was also given the opportunity to work directly with clinicians as a Visiting Scientist at Mayo Clinic. In addition to his Harvard MBA, Braly holds an SM in health sciences and technology from MIT through the Harvard-MIT Division of Health Sciences and Technology and a BS in biomedical engineering from Johns Hopkins University.